Hipra

Industry

Diagnostics, Fishery & aquaculture, Veterinary

Topics

Animal & aquaculture vaccines

Role

Producer — “…three R&D centers, and six manufacturing facilities. Key developments include the 2025 inauguration of the HIP…”

Why it is bioeconomy

Hipra is a pharmaceutical company focused on animal and human health vaccines, which falls outside the scope of the bioeconomy definition provided.

Not yet cited as a supplier in a graded solution.

Subsidiaries: Hipra Scientific S.L.U. · Hipra Human Health S.L.U. · GoodGut S.L.U. · Hipra Biotech Services, S.A.

• 2026-09 Latest status: The company continues to operate and expand, recently receiving European Commission marketing authorisation for an updated COVID-19 vaccine in July 2026 and announcing its availability in the UK in September 2026. ↗ ↗ ↗
• 2026-06-22 Hipra rompe el techo de los 500 millones y busca ser referente de la autonomía biotecnológica europea | Empresas | Cinco Días
  Hipra is a Spanish biofarmaceutical group that surpassed 500 million euros in revenue, driven by its strong veterinary vaccines while aggressively expanding into human health, with plans to accelerate biotech autonomy in Europe (including a sizable …
• 2026-02-04 HIPRA, premiada por el Ministerio de Industria por impulsar la autonomía estratégica con ‘Bien Hecho en España’ - Pharmatech
  HIPRA recibe el premio “Bien Hecho en España” por impulsar la autonomía estratégica vía liderazgo biotecnológico, capacidad productiva propia y enfoque One Health, destacando su papel en la vacuna española contra la COVID-19 y proyectos europeos para acelerar …
• 2026-05-29 El secretario de Estado de Ciencia visita el Campus de Hipra en Aiguaviva y se interesa por su apuesta por el One Health
  Hipra is showcased as a key player linking research, biotechnology, and industrial capabilities under the One Health approach, contributing to Europe’s health preparedness and global health security. The visit highlights Hipra’s role in strengthening …
• 2026-07-24 La española Hipra recibe la opinión positiva de Europa para su vacuna Covid-19 contra la variante XFG.1.1
  Hipra has received a positive opinion from the European Medicines Agency’s CHMP to update its recombinant Covid-19 vaccine, Bimervax, for the XFG.1.1 variant, moving toward EU authorization. The updated vaccine will be available in vial and a new prefilled …
• 2026-07-24 Hipra da un nuevo paso hacia la comercialización de su vacuna contra la covid - Infobae
  Hipra, la farmacéutica catalana que fabrica la vacuna española Bimervax contra la covid, obtuvo una opinión favorable del CHMP de la EMA para adaptar su vacuna a la variante XFG.1.1, acercando la autorización de venta para la campaña 2026-27.
• 2026-07-31 La Comisión Europea da luz verde a la vacuna COVID-19 de HIPRA adaptada a XFG.1.1
  HIPRA has received EU marketing authorization for BIMERVAX®, its adjuvanted recombinant protein COVID-19 vaccine updated to the XFG.1.1 variant, including monodose vial and a prefilled syringe, for individuals 12 and older for the 2026/2027 vaccination …

Ownership & investors 4

Partners & deals 1

Similar companies

Benchmark Vaccines Limited · CZ Vaccines · Lohmann Animal Health · CEVA SANTE ANIMALE · PHARMAQ part of Zoetis · Dopharma B.V. · AQUATRECK ANIMAL HEALTH S.L · VEROVACCiNES GmbH